Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1994-2-17
|
| pubmed:abstractText |
Seventy metastatic breast adenocarcinoma patients, pretreated with standard hormonotherapy or chemotherapy, received continuous UFT at 10 mg/kg/day, orally, for at least two months. There were one complete response (1.5%), 12 partial responses (17%), one minor response and 37 disease stabilizations. The median duration of response was nine months. A greater efficacy was demonstrated in 29 patients with soft tissue disease, with a rate of 38% objective responses. The major toxicity was gastrointestinal, with 45% of patients developing nausea and vomiting and 30%, diarrhea. Bone marrow toxicity was slight. UFT has shown antitumor activity in our group of pretreated patients, especially these with the cutaneous tumoral and/or inflammatory form of the disease.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0368-2811
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
363-5
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:8283790-Adenocarcinoma,
pubmed-meshheading:8283790-Administration, Oral,
pubmed-meshheading:8283790-Adult,
pubmed-meshheading:8283790-Aged,
pubmed-meshheading:8283790-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8283790-Asthenia,
pubmed-meshheading:8283790-Bone Neoplasms,
pubmed-meshheading:8283790-Breast Neoplasms,
pubmed-meshheading:8283790-Capsules,
pubmed-meshheading:8283790-Chemotherapy, Adjuvant,
pubmed-meshheading:8283790-Diarrhea,
pubmed-meshheading:8283790-Female,
pubmed-meshheading:8283790-Humans,
pubmed-meshheading:8283790-Middle Aged,
pubmed-meshheading:8283790-Nausea,
pubmed-meshheading:8283790-Remission Induction,
pubmed-meshheading:8283790-Soft Tissue Neoplasms,
pubmed-meshheading:8283790-Tegafur,
pubmed-meshheading:8283790-Uracil,
pubmed-meshheading:8283790-Vomiting
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Phase II trial of UFT activity in pretreated breast cancer patients.
|
| pubmed:affiliation |
Servicío de Coordinación Oncológica, Hospital Clínic i Provincial, Barcelona, Spain.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|